Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: In vitro and in vivo correlation

被引:80
作者
Meletiadis, Joseph
Petraitis, Vidmantas
Petraitiene, Ruta
Lin, Pengxin
Stergiopoulou, Theodouli
Kelaher, Amy M.
Sein, Tin
Schaufele, Robert L.
Bacher, John
Walsh, Thomas J. [1 ]
机构
[1] NCI, Ctr Canc Res, Pediat Oncol Branch, Immunocompromised Host Sect,NIH, Bethesda, MD 20892 USA
[2] NIH, Surg Serv, Div Vet Resources, Off Res Serv, Bethesda, MD 20892 USA
[3] Sci Applicat Int Corp, Frederick, MD USA
关键词
LIPOSOMAL AMPHOTERICIN-B; PERSISTENTLY NEUTROPENIC RABBITS; DRUG-INTERACTION MODELS; COMBINATION THERAPY; PLASMA PHARMACOKINETICS; ANTIFUNGAL THERAPY; ITRACONAZOLE; EFFICACY; RAVUCONAZOLE; AGENTS;
D O I
10.1086/506617
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Combination antifungal therapy is increasingly used in the treatment of invasive aspergillosis. Whether the interaction between amphotericin B and triazoles is antagonistic against invasive aspergillosis is a controversial issue that is not likely to be resolved through a randomized clinical trial. Here, we found both in vitro and in vivo antagonism between liposomal amphotericin B and ravuconazole in simultaneous treatment of experimental invasive pulmonary aspergillosis in persistently neutropenic rabbits. Bliss independence-based drug-interaction modeling showed significant antagonism in vitro and in vivo, with the observed drug effects being 20%-69% lower than would be expected if the drugs were acting independently. These in vitro and in vivo findings of antagonism were consistent with the findings from Loewe additivity-based drug-interaction modeling. No pharmacokinetic interaction was found. The combination of a triazole and polyene may be antagonistic in the treatment of invasive pulmonary aspergillosis.
引用
收藏
页码:1008 / 1018
页数:11
相关论文
共 45 条
[1]  
[Anonymous], 2002, Approved Standard M38-A
[2]   Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans [J].
Bekersky, I ;
Fielding, RM ;
Dressler, DE ;
Lee, JW ;
Buell, DN ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :828-833
[3]  
BERENBAUM MC, 1989, PHARMACOL REV, V41, P93
[4]   CRITERIA FOR ANALYZING INTERACTIONS BETWEEN BIOLOGICALLY-ACTIVE AGENTS [J].
BERENBAUM, MC .
ADVANCES IN CANCER RESEARCH, 1981, 35 :269-335
[5]   Newer systemic antifungal agents - Pharmacokinetics, safety and efficacy [J].
Boucher, HW ;
Groll, AH ;
Chiou, CC ;
Walsh, TJ .
DRUGS, 2004, 64 (18) :1997-2020
[6]   Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis [J].
Chandrasekar, PH ;
Cutright, JL ;
Manavathu, EK .
CLINICAL MICROBIOLOGY AND INFECTION, 2004, 10 (10) :925-928
[7]   Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis [J].
Clemons, KV ;
Espiritu, M ;
Parmar, R ;
Stevens, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) :4867-4875
[8]  
CORNLEY OA, 2005, AM SOC HEM 47 ANN M
[9]   INVITRO SUSCEPTIBILITY AND SYNERGY STUDIES OF ASPERGILLUS SPECIES TO CONVENTIONAL AND NEW AGENTS [J].
DENNING, DW ;
HANSON, LH ;
PERLMAN, AM ;
STEVENS, DA .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1992, 15 (01) :21-34
[10]   In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models [J].
Dorsthorst, DTAT ;
Verweij, PE ;
Meis, JFGM ;
Punt, NC ;
Mouton, JW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (06) :2007-2013